U.S. markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
79.70-0.57 (-0.71%)
At close: 04:00PM EST
80.00 +0.30 (+0.38%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close80.27
Bid79.76 x 800
Ask80.19 x 800
Day's Range79.34 - 80.59
52 Week Range79.34 - 98.52
Avg. Volume2,121,818
Market Cap178.296B
Beta (5Y Monthly)0.53
PE Ratio (TTM)18.41
EPS (TTM)4.33
Earnings DateN/A
Forward Dividend & Yield3.20 (3.96%)
Ex-Dividend DateMar 04, 2021
1y Target Est104.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NVS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novartis AG
    Market Digest: NVS, IFF, PRU, SPH, XYL, PINS, DELLStocks were mixed on Thursday amid continued inflation concerns. The Technology and Materials sectors finished higher while Industrials, Communication Services, and Utilities declined. Disney shares fell sharply following weaker-than-expected 4Q results and disappointing subscriber growth in the Disney+ streaming service. Electric vehicle maker Rivian jumped 22% and has now risen more than 50% since its Wednesday IPO. The Dow fell 0.44%, the S&P rose 0.06%, and the Nasdaq rose 0.52%. Crude oil fell slightly to $81 per barrel, while gold rose $16 to $1865 per ounce.
    Fair Value
    Economic Moat
    19 days agoArgus Research
View more
  • Reuters

    Novartis chairman says all options open for Sandoz unit - report

    Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday. Asked whether Novartis could merge Sandoz with either Israel's Teva or U.S.-based Viatris or divest it, Joerg Reinhardt said: "All options are open for us." Reinhardt said Novartis's innovative pharma business and the generics business had drifted further apart over the last years so it made sense to examine options now.

  • Zacks

    Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why

    Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.

  • Reuters

    Roche shareholders approve deal to buy Novartis's $20.7 billion stake

    Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said. Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades. Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.